

**TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS**

**A. For Equity Issues**

Sr No      Name of the issue:      Qualitek Labs Limited

1	Type of issue (IPO/ FPO)		Initial Public Offering (IPO) on SME Platform of BSE
---	--------------------------	--	--

Source: Prospectus of the Company

2	Issue size		
	Fresh Issue Size (Rs. Lakhs)		1,964.40
	Source: Prospectus of the Company		

3	Grade of issue alongwith name of the rating agency		Not applicable
---	--	--	----------------

Source: Prospectus of the Company

4	Subscription level (number of times)		117.73 times
	Source: Final post-issue report dated	JANUARY 29, 2024	

5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement)		
	Particulars		%
	(i) allotment in the issue		0
	(ii) at the end of the 1st Quarter immediately after the listing of the issue		0.00
	(iii) at the end of 1st FY		0.00
	(iv) at the end of 2nd FY		0.00
	(v) at the end of 3rd FY		0.00

(1) Source: Basis of Allotment (2) Source: Shareholding pattern as available on BSE

6	Financials of the issuer (Standalone)			
		Amount in Lakhs		
	Parameters	1st FY (For the period ended March 31, 2023)	2nd FY (For the period ended March 31, 2024) (1)	3rd FY (For the period ended March 31, 2025)*
	Income from operations	1913.66	2918.38	-
	Net Profit for the period	296.91	430.73	-
	Paid-up equity share capital	540.75	737.19	-
	Reserves excluding revaluation reserves	445.77	2507.71	-

\*Financials not disclosed as reporting for the relevant fiscal year has not been completed.

(1) Source: Annual Report of the Company for relevant FY

7	Trading status in the scrip of the issuer (i) Company's Equity Shares are listed on BSE Limited (SME Platform). (ii) The Shares have not been suspended or delisted.		
	Particulars		Status
	(i) at the end of 1st FY (March 31, 2023)*		Active
	(ii) at the end of 2nd FY (March 31, 2024)*		Active
	(iii) at the end of 3rd FY (March 31, 2025)*		*NA

\*Trading status not disclosed as the relevant fiscal year has not been completed

Source: BSE

8	Change, if any, in directors of issuer from the disclosures in the offer document			
	Particulars	Name of the Director	Appointed / Resigned	
	(i) at the end of 1st FY	NOT APPLICABLE	NOT APPLICABLE	
	(ii) at the end of 2nd FY	NOT APPLICABLE	NOT APPLICABLE	
	(iii) at the end of 3rd FY	NOT APPLICABLE	NOT APPLICABLE	

Source: MCA

9

**Status of implementation of project/ commencement of commercial production**

(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the Issue as per Prospectus

Particulars	Total Estimated Fund Requirement	Estimated Utilization
Not Applicable		

(ii) Actual implementation

Particulars	Total Estimated Fund Requirement	Estimated Utilization
Not Applicable		

(iii) Reasons for delay in implementation, if any

10

**Status of utilization of issue proceeds (as submitted to stock exchanges under Clauses 41, 43 and 43A of the listing agreement)**

(i) as disclosed in the offer document

(₹in Lakhs)

Expenditure Items	Total Estimated Cost	Already Incurred	Estimated Utilisation of Net Proceeds (Financial Year 2023- 24)	Total
Funding capital expenditure towards installation of plant and machinery for new & existing laboratories and for expansion of laboratories	622.38	-	622.38	622.38
Repayment of unsecured loans to Promoter	818.16		818.16	818.16
Funding of working capital requirements	250		250	250
General Corporate Purposes	140.64	-	140.64	140.64
<b>Total</b>				<b>1831.18</b>

Source: Prospectus of the company

(ii) Actual utilization

Expenditure Items	Total Estimated Cost	Total amount utilised upto fiscal 2023- 24	Total fund utilised upto F.Y. 2024
Funding capital expenditure towards installation of plant and machinery for new & existing laboratories and for expansion of laboratories	622.38	210.16	412.22
Repayment of unsecured loans to Promoter	818.16	818.16	0
Funding of working capital requirements	250	196.6	53.4
General Corporate Purposes	140.64	52.91	87.73

Source: Company

(iii) Reasons for deviation, if any

Not applicable

11

**Comments of monitoring agency, if applicable (See Regulation 16 of SEBI (ICDR) Regulations, 2009 read with Clause 43A of the listing agreement)**

(a) Comments on use of funds	Not Applicable, since Issue size is less than Rs. 100 crores
------------------------------	--

**TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS**

<i>(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document</i>	<i>Not Applicable</i>
<i>(c) Any other reservations expressed by the monitoring agency about the end use of funds</i>	<i>Not Applicable</i>

*(To be submitted till the time the issue proceeds have been fully utilised)*

12

**Price- related data**

Issue price (Rs): 100

Price parameters	At close of listing day	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of 1st FY after the listing of the issue			As at the end of 2nd FY after the listing of the issue			As at the end of 3rd FY after the listing of the issue		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
<b>Market Price (BSE)</b>	<b>199.50</b>	163.00	158.50	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Index (of the Designated Stock Exchange): BSE Sensex</b>	<b>71941.57</b>	73095.22	74671.28	NA	NA	NA	NA	NA	NA	NA	NA	NA
<b>Sectoral Index (mention the index that has been considered and reasons for considering the same)</b>	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Source: BSE

Note: 1. Where the 30th day / 90th day / March 31 of a particular year falls on a BSE trading holiday, the immediately following trading day has been considered

Note: 2. Where the 30th day / 90th day / March 31 of a particular year falls on the day when there is no trade in equity share of the Company , preceding trading day has been considered

13

**Basis for Issue Price**

Accounting ratio	Name of company	As disclosed in the offer document for Period ending March 31, 2023	At the end of 1st FY (2023-24)	At the end of 2nd FY (2024-25)#	At the end of 3rd FY (2025-26)#
<b>EPS</b>	<b>Issuer:</b>	7.45	NA	-	-
	<b>Peer:Choksi Laboratories Ltd.</b>	4.69	NA		
<b>P/E based on the Basic &amp; Diluted EPS</b>	<b>Issuer:</b>	13.43	NA		
	<b>Peer:Choksi Laboratories Ltd.</b>	11.74	NA	-	-
<b>RoNW</b>	<b>Issuer:</b>	30.1	NA	-	-
	<b>Peer:Choksi Laboratories Ltd.</b>	6.58	NA		
<b>NAV</b>	<b>Issuer:</b>	24.74	NA	-	-
	<b>Peer:Choksi Laboratories Ltd.</b>	<b>30.31</b>	NA		

#Not Available

14

**Any other material information**

Nil

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Oneview Corporate Advisors Private Limited ("OCAPL") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") ( the "Stock Exchange"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.